Aytu BioPharma Highlights Opportunity for EXXUATM (gepirone) as New Way to Treat Major Depressive Disorder That Avoids Common Side Effects of Sexual Dysfunction and Significant Weight Gain following launch of EXXUA

Stock Information for Aytu BioPharma, Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Aytu BioPharma, Inc.

Aytu BioPharma to Present at the Planet MicroCap Las Vegas 2026 Investor Conference on June 17, 2026
Aytu BioPharma to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
Aytu BioPharma Reports Fiscal 2026 Third Quarter Operational and Financial Results
Aytu BioPharma to Report Fiscal 2026 Third Quarter Operational and Financial Results on May 13, 2026
Aytu BioPharma Reports Fiscal 2026 Second Quarter Operational and Financial Results
Aytu BioPharma to Report Fiscal 2026 Second Quarter Operational and Financial Results on February 3, 2026
Aytu BioPharma Recaps Investor Day Held on January 20, 2026
Aytu BioPharma to Participate in the Lytham Partners 2026 Investor Healthcare Summit on January 15, 2026

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.